Brainstorm Cell Therapeutics (BCLI) Tops Q2 EPS by 2c
Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q2 EPS of ($0.12), $0.02 better than the analyst estimate of ($0.14).
For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.